CN102482254A - (s)-n-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺盐酸盐(度洛西汀)的结晶方法 - Google Patents

(s)-n-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺盐酸盐(度洛西汀)的结晶方法 Download PDF

Info

Publication number
CN102482254A
CN102482254A CN2010800392370A CN201080039237A CN102482254A CN 102482254 A CN102482254 A CN 102482254A CN 2010800392370 A CN2010800392370 A CN 2010800392370A CN 201080039237 A CN201080039237 A CN 201080039237A CN 102482254 A CN102482254 A CN 102482254A
Authority
CN
China
Prior art keywords
duloxetine
crystal
solvent
crystallization
scope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800392370A
Other languages
English (en)
Chinese (zh)
Inventor
L·里德万
约瑟夫·希尼布克
V·格沃多娃
哈纳·布索瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of CN102482254A publication Critical patent/CN102482254A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CN2010800392370A 2009-09-02 2010-09-02 (s)-n-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺盐酸盐(度洛西汀)的结晶方法 Pending CN102482254A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CZPV-2009-584 2009-09-02
CZ2009-584A CZ304602B6 (cs) 2009-09-02 2009-09-02 Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
PCT/CZ2010/000099 WO2011026449A1 (en) 2009-09-02 2010-09-02 A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine)

Publications (1)

Publication Number Publication Date
CN102482254A true CN102482254A (zh) 2012-05-30

Family

ID=43413356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800392370A Pending CN102482254A (zh) 2009-09-02 2010-09-02 (s)-n-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺盐酸盐(度洛西汀)的结晶方法

Country Status (11)

Country Link
EP (1) EP2473497A1 (enExample)
JP (1) JP2013503823A (enExample)
KR (1) KR20120047262A (enExample)
CN (1) CN102482254A (enExample)
BR (1) BR112012004862A2 (enExample)
CZ (1) CZ304602B6 (enExample)
EA (1) EA021528B1 (enExample)
IL (1) IL218329A0 (enExample)
MX (1) MX2012002621A (enExample)
WO (1) WO2011026449A1 (enExample)
ZA (1) ZA201201570B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀晶型及其制备方法
CN104478849A (zh) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 制备去甲肾上腺素再摄取双重抑制剂的方法
CN106265528A (zh) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 制备药物凝集体的方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016222628A (ja) * 2015-06-03 2016-12-28 株式会社トクヤマ デュロキセチン塩酸塩の製造方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108386A1 (en) * 2004-05-11 2005-11-17 Cipla Limited Crystalline forms of duloxetine free base
WO2006045255A1 (en) * 2004-10-26 2006-05-04 Zentiva, A.S. Method of manufacturing (s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine)
WO2006099433A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Pure duloxetine hydrochloride
WO2007093439A1 (en) * 2006-02-17 2007-08-23 Krka Processes for the preparation of crystalline forms of duloxetine hydrochloride
WO2007148102A2 (en) * 2006-06-23 2007-12-27 Arrow International Limited Crystalline duloxetine hydrochloride
WO2007148096A1 (en) * 2006-06-23 2007-12-27 Arrow International Limited Crystalline duloxetine hydrochloride

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
DE10212301A1 (de) 2002-03-20 2003-10-02 Bayer Ag Verfahren zur Herstellung von Aryl-aminopropanolen
DK1539673T3 (da) 2002-07-09 2008-01-21 Lonza Ag Fremgangsmåde til fremstilling af N-monosubstituerede beta-aminoalkoholer
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
WO2008107911A2 (en) * 2007-03-05 2008-09-12 Lupin Limited Novel process for preparation of duloxetine hydrochloride

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108386A1 (en) * 2004-05-11 2005-11-17 Cipla Limited Crystalline forms of duloxetine free base
WO2006045255A1 (en) * 2004-10-26 2006-05-04 Zentiva, A.S. Method of manufacturing (s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine)
WO2006099433A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Pure duloxetine hydrochloride
WO2006099468A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Process for the purification of duloxetine hydrochloride
WO2007093439A1 (en) * 2006-02-17 2007-08-23 Krka Processes for the preparation of crystalline forms of duloxetine hydrochloride
WO2007148102A2 (en) * 2006-06-23 2007-12-27 Arrow International Limited Crystalline duloxetine hydrochloride
WO2007148096A1 (en) * 2006-06-23 2007-12-27 Arrow International Limited Crystalline duloxetine hydrochloride

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀晶型及其制备方法
CN104478849A (zh) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 制备去甲肾上腺素再摄取双重抑制剂的方法
CN106265528A (zh) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 制备药物凝集体的方法

Also Published As

Publication number Publication date
EP2473497A1 (en) 2012-07-11
BR112012004862A2 (pt) 2015-09-08
JP2013503823A (ja) 2013-02-04
ZA201201570B (en) 2013-08-28
MX2012002621A (es) 2012-07-03
IL218329A0 (en) 2012-04-30
WO2011026449A1 (en) 2011-03-10
EA201290127A1 (ru) 2013-02-28
CZ2009584A3 (cs) 2011-03-09
CZ304602B6 (cs) 2014-07-30
EA021528B1 (ru) 2015-07-30
KR20120047262A (ko) 2012-05-11

Similar Documents

Publication Publication Date Title
CA2114678C (en) Crystals of n-(trans-4-isopropylcyclohexylcarbonyl)- d-phenylalanine and methods for preparing them
US5463116A (en) Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
JP2008504326A (ja) （−）−（１ｒ，２ｒ）−３−（３−ジメチルアミノ−１−エチル−２−メチルプロピル）−フェノール塩酸塩の結晶形
BRPI0617477A2 (pt) mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
CN102482254A (zh) (s)-n-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺盐酸盐(度洛西汀)的结晶方法
Liu et al. Spherulitic growth strategy: Improving the stability of metastable form and particle performances of m-aminobenzoic acid
CN112707829B (zh) 一种妥洛特罗晶型及制备方法
CN102336818B (zh) 一种肽类物质的晶体及其制备方法和用途
TWI727517B (zh) 貝前列素-314d晶體及其製備方法
CN112638865B (zh) 药物共晶体及其制备方法
TW202126614A (zh) 十六烷基曲前列環素晶體及其製備方法
JP2025031139A (ja) ジヒドロスフィンゴミエリンの結晶、及び、その製造方法、並びに、医薬組成物
CN114605340B (zh) 一种邻香兰素-吡嗪酰胺共晶及其制备方法
HK1169108A (en) A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine)
CN114133378B (zh) 一种盐酸尼洛替尼共晶及其制备方法
CN116143647A (zh) 双氯芬酸二乙胺的新晶型及其制备方法
CN115160393B (zh) 一种银-核苷五元环络合物超分子水凝胶及其制备方法
AU2004249526B2 (en) A method for the preparation of crystalline dexloxiglumide
CN118126105B (zh) 一种孕烯醇酮新晶型及其制备方法
CN119591655A (zh) 一种球状晶体的麦角甾醇及其制备方法
WO2025032197A1 (en) Crystalline form of 5-((3r,5s)-3-amino-5-trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile
CN106674156A (zh) 多西他赛新晶型及其制备方法
WO2016097156A1 (en) Novel solvates of n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamide
WO2023173561A1 (zh) 氘代尼马瑞韦晶型i及其制备方法
CN105646275A (zh) 一种左米那普伦化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1169108

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120530